Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical preparation for treating hepatitis B, and preparation method and application thereof

A pharmaceutical preparation, technology for hepatitis B, applied in the field of biomedicine

Pending Publication Date: 2020-06-30
JIANGSU THERAVAC BIO PHARMA
View PDF5 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For example, vaccination with aluminum-containing adjuvant can cause some adverse reactions, such as erythema, subcutaneous nodules, contact hypersensitivity, granuloma, myofascitis, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical preparation for treating hepatitis B, and preparation method and application thereof
  • Pharmaceutical preparation for treating hepatitis B, and preparation method and application thereof
  • Pharmaceutical preparation for treating hepatitis B, and preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] The preparation of each component of embodiment 1 therapeutic hepatitis B vaccine preparation

[0051] 1. Preparation of HBsAg stock solution:

[0052] The amino acid sequence of the HBsAg protein is shown in SEQ ID NO.1.

[0053] The HBsAg protein is prepared by HBsAg gene recombinant yeast cells, and the yeast cell types include Hansenula, Saccharomyces and Pichia, preferably Hansenula.

[0054] For the specific preparation steps, refer to the Chinese patent application CN108330145A, the HBsAg gene recombinant Hansenula cells are fermented and cultured, and the cells are harvested. The HBsAg stock solution was prepared by bacteria-breaking treatment, silica gel adsorption, column chromatography and TFF purification. The prepared HBsAg stock solution is required to have a purity greater than 95% and a protein content of not less than 200 μg / ml. The residues of host DNA, host protein and other chemical substances are in compliance with the Pharmacopoeia regulations...

Embodiment 2

[0063] The preparation of embodiment 2 therapeutic hepatitis B vaccine preparations

[0064] 1. PBS buffer solution: Na 2 HPO 4 12H 2 O 2.0g, NaH 2 PO 4 2H 2 O 2.4g, NaCl 9g, add water to dissolve and dilute to 1000ml, adjust the pH value to 7.20 with hydrochloric acid or sodium hydroxide;

[0065] 2. 0.5% polysorbate 80 (Tween 80) solution: weigh 5.0 g of Tween 80 and dilute to 1000 ml with PBS buffer solution;

[0066] 3. HBsAg solution: get the HBsAg stock solution (prepared in Example 1), add 0.5% Tween 80 solution, and dilute the concentration of Tween 80 to 0.05% with PBS buffer solution;

[0067] 4. HBcAg solution: take the HBcAg stock solution (prepared in Example 1), add 0.5% Tween 80 solution, and dilute the concentration of Tween 80 to 0.05% with PBS buffer solution;

[0068] 5. CpG solution: take CpG (prepared in Example 1) and dissolve and dilute it with PBS buffer solution to obtain a CpG stock solution, add 0.5% Tween 80 solution, and dilute the concent...

Embodiment 3

[0070] The screening test of embodiment 3 therapeutic hepatitis B vaccine preparation prescriptions

[0071] Among the three components of HBsAg, HBcAg and CpG, HBsAg was most affected by various factors and had the worst stability. Therefore, HBsAg was used as an index to screen the formulation prescription.

[0072] HBsAg mainly exists in the form of virus-like particles (hereinafter referred to as VLP), and the main peak area detected by HPLC represents the amount of VLP in the preparation. Therefore, a decrease in the area of ​​the main peak represents a decrease in the amount of HBsAg in the VLP form in the formulation.

[0073] 1) Screening of buffer system

[0074] Solution preparation:

[0075] 1.0.5% polysorbate 80 (Tween 80) solution is made by embodiment 2;

[0076] 2. Histidine buffer solution: histidine 1.55g, histidine hydrochloride 2.095g, add water to dissolve and dilute to 1000ml.

[0077] 3. HBsAg solution (PBS buffer solution): Take the HBsAg stock so...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical preparation for treating hepatitis B, and a preparation method and application thereof. The pharmaceutical preparation comprises a hepatitis B surface antigensolution, further comprises a hepatitis B core antigen solution and further comprises an oligodeoxynucleotide solution. The pharmaceutical preparation does not contain sugar, has simple components, does not have adverse reactions caused by aluminum adjuvant, and has good antigen stability. The pharmaceutical preparation shows a good preservation effect in a long-term stability experiment, can meet production, storage and use requirements of vaccines, and is suitable for large-scale production and use of therapeutic hepatitis B vaccines.

Description

[0001] This application claims the priority of the Chinese invention patent application titled "Pharmaceutical preparation for the treatment of hepatitis B and its preparation method and application" submitted on December 24, 2018, with application number 2018115804704. technical field [0002] The invention belongs to the field of biomedicine, and relates to a pharmaceutical preparation for treating hepatitis B, a preparation method and application thereof. Background technique [0003] Hepatitis B virus (HBV) infection is one of the serious public health problems worldwide. HBV infection is an important cause of chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma (Fattovich G.J. Hepatol. 2008; 48:335-352). The commonly used drugs for clinical treatment of chronic HBV infection mainly include nucleoside analogues and interferon. Nucleoside analogs cannot completely remove cccDNA in liver cells, and long-term use can easily lead to the emergence of drug-resist...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/29A61K39/39A61K47/26A61K47/02A61P1/16A61P31/20A61P35/00
CPCA61K39/12A61K39/39A61K47/26A61K47/02A61P1/16A61P31/20A61P35/00A61K2039/575A61K2039/572A61K2039/55561C12N2730/10134A61K9/08A61K9/0019A61K47/183A61K9/19C07K14/005C12N2730/10122A61P37/04A61K39/292
Inventor 李建强葛君任苏林黄红颖孙娇娇孙洪林周童顾月陈晓晓周雪
Owner JIANGSU THERAVAC BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com